Naringenin for Health & Longevity - Quick Reference Sheet

Naringenin for Health & Longevity

Created on 10/08/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Sonnet 5.5 – Audit

Naringenin is a citrus plant compound sold as a supplement for metabolic and aging support. Human evidence is small: a few trials, mostly from one group in people with fatty liver, report better cholesterol and triglyceride levels and less liver fat, the latter not yet repeated independently. Longevity, muscle, bone and brain-aging claims rest on animal and cell studies. Safety concerns are theoretical or indirect; no long-term data exist. (Full Review)

Protocol

Fatty liver trial regimen
100 mg capsules twice daily
For 4 weeks
Time of day
Before meals
Before lunch and dinner in the fatty liver trial; no timing study exists
Higher-dose regimens
150 mg three times daily
For 8 weeks in one participant; 300 mg twice daily was proposed from blood-level data but not tested for efficacy
Time to effect
Blood Lipid Profile
Within 4 weeks
Changes appeared in one trial
Liver Fat Grade in Fatty Liver Disease
Within 4 weeks
Changes appeared in one trial

Benefits

Contraindications
  • CYP3A4 or OATP substrate drugs with a narrow margin between effective and toxic dose (tacrolimus, dasatinib, fexofenadine, aliskiren) without prescriber review (theoretical)
  • Congenital long QT syndrome or use of QT-prolonging drugs (amiodarone, sotalol, haloperidol; theoretical for purified naringenin)
  • Hormone-sensitive cancers such as breast or endometrial cancer (theoretical)
  • Pregnancy and lactation (theoretical)
  • Advanced kidney failure (blood creatinine above 1.4 mg/dL) or liver cirrhosis (theoretical)
Key Interactions
  • OATP substrate drugs (fexofenadine, also OTC; aliskiren): Caution (theoretical for naringenin)
  • CYP3A4 substrate drugs (felodipine, simvastatin, atorvastatin, tacrolimus, dasatinib): Caution (theoretical for naringenin)
  • Glucose-lowering drugs (insulin, metformin, glimepiride): Monitor (theoretical)
  • Lipid-lowering drugs (atorvastatin, rosuvastatin, ezetimibe): Monitor (theoretical)
  • Hormone therapies (tamoxifen, anastrozole, estradiol): Caution (theoretical for purified naringenin)
  • Other lipid- or glucose-lowering supplements (berberine, red yeast rice, niacin): Monitor (theoretical)
  • Other estrogen-active plant compounds (soy isoflavones, red clover): Monitor (theoretical)
  • Other CYP3A4 or transporter inhibitors (curcumin with piperine, bergamot, grapefruit extracts): Monitor (theoretical)
  • Other citrus flavonoids (hesperetin, quercetin): Informational (no clinical consequence identified)
  • Probiotics: Informational
  • Grapefruit juice and citrus products: Caution

Risk & Side Effects

  • Low: Non-Serious Adverse Events at Single Doses; Reduced Absorption of OATP1A2 Substrate Drugs; QT Prolongation and Cardiac Ion Channel Blockade
  • Speculative: CYP3A4 Enzyme Inhibition; Estrogen Receptor Activity; Reproductive and Developmental Toxicity at High Doses

Monitoring

Marker Target Why
Alanine aminotransferase and aspartate aminotransferase Approx. 7–55 U/L and 8–48 U/L (standard reference range) Safety check: rising values would stop use
Creatinine 0.6–1.3 mg/dL (standard reference range) Safety check: kidney function
LDL cholesterol, triglycerides, HDL cholesterol No established target; track change from the individual's own baseline Expected-change marker: lipid effect in fatty liver trial
Fasting glucose and insulin Insulin approx. 2–25 µIU/mL (standard reference range); glucose: no established target, track change from the individual's own baseline Expected-change marker: insulin fell 18% in one case
QTc interval (electrocardiogram) No established target; track change from the individual's own baseline Safety check: relevant with QT-prolonging drugs

Cadence: Baseline before starting, then 4 weeks, 12 weeks, then every 6–12 months; the cadence reflects common practice rather than evidence, as trials ran only 4–8 weeks

Qualitative Assessment

  • Gastrointestinal tolerance (abdominal pain, nausea)
  • Energy level and exercise capacity
  • Body weight and waist circumference
  • Unusual symptoms of higher drug exposure in people using CYP3A4 or OATP substrate medications